Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
7 The phase 3 SURMOUNT-4 trial (NCT04660643), conducted by Aronne et al, included 670 participants with overweight or obesity without diabetes who were followed for 52 weeks after completing a maximum-tolerated tirzepatide lead-in regimen for 36 weeks
Results of the current studies support the hypothesis that the combination of amylin with GLP-1-based pharmacotherapy, in particular a stepwise-administration of sCT and liraglutide, results in a greater suppression of feeding, body weight and adiposity compared to administration of amylin or GLP-1 analogs alone
Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes
Study: Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression
The genuine unknown is long-term effects in humans
